We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

7 hedge funds and large institutions have $13.8M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 229 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% less funds holding in top 10

Funds holding in top 10: 321 (-31)

97% less funds holding

Funds holding: 2407 (-233)

99% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 229

100% less capital invested

Capital invested by funds: $8.78B → $13.8M (-$8.77B)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
7
Holders Change
-233
Holders Change %
-97.08%
% of All Funds
0.11%
Holding in Top 10
1
Holding in Top 10 Change
-31
Holding in Top 10 Change %
-96.88%
% of All Funds
0.02%
New
2
Increased
Reduced
4
Closed
229
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
-$151M -1,000,497 Closed
WCMNY
27
Westchester Capital Management (New York)
New York
-$143M -945,499 Closed
Capital World Investors
28
Capital World Investors
California
-$127M -841,900 Closed
UBS Group
29
UBS Group
Switzerland
-$126M -833,464 Closed
ClearBridge Investments
30
ClearBridge Investments
New York
-$126M -830,668 Closed
Brown Advisory
31
Brown Advisory
Maryland
-$114M -752,048 Closed
EP
32
Eversept Partners
New York
-$96.3M -637,139 Closed
Norges Bank
33
Norges Bank
Norway
-$95.8M -633,780 Closed
AAM
34
Alpine Associates Management
Florida
-$93M -615,200 Closed
Balyasny Asset Management
35
Balyasny Asset Management
Illinois
-$92.3M -610,571 Closed
Northern Trust
36
Northern Trust
Illinois
-$86.6M -572,845 Closed
Morgan Stanley
37
Morgan Stanley
New York
-$85.6M -565,941 Closed
Charles Schwab
38
Charles Schwab
California
-$73.9M -489,030 Closed
Tudor Investment Corp
39
Tudor Investment Corp
Connecticut
-$71.8M -475,004 Closed
Bank of America
40
Bank of America
North Carolina
-$64.7M -427,832 Closed
AGM
41
Alpine Global Management
New York
-$56.5M -373,999 Closed
MF
42
Magnetar Financial
Illinois
-$54.9M -363,372 Closed
Citigroup
43
Citigroup
New York
-$54.6M -361,076 Closed
T. Rowe Price Associates
44
T. Rowe Price Associates
Maryland
-$53.9M -356,257 Closed
BCM
45
Bluefin Capital Management
New York
-$51.6M -341,250 Closed
AllianceBernstein
46
AllianceBernstein
Tennessee
-$47.5M -314,412 Closed
FTCM
47
First Trust Capital Management
Illinois
-$43.7M -288,887 Closed
American Century Companies
48
American Century Companies
Missouri
-$43.5M -287,812 Closed
Allspring Global Investments
49
Allspring Global Investments
North Carolina
-$43.4M -287,350 Closed
TCM
50
Tang Capital Management
California
-$42.3M -280,000 Closed

BHVN Hedge Fund Activity: Q4 2022 in Review

7 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2022, worth a combined $13.8M — down 100% from $8.78B a quarter earlier.

Sellers outnumbered buyers: 229 funds closed out of BHVN and 2 opened new positions — a net loss of 227 holders — while 4 trimmed existing stakes and 0 added.

The largest buyer was Blue Trust Inc, opening a new position worth an estimated $9.87K. The largest seller was BlackRock, exiting entirely with an estimated $748M sold.

  • 7 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2022, down from 240 in Q3 2022.
  • Funds reported $13.8M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2022, down 100% quarter-over-quarter.
  • 2 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2022 and 229 closed out, a net change of -227 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2022 was Blue Trust Inc, an estimated $9.87K added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2022 was BlackRock, an estimated $748M sold.

Based on aggregated 13F filings for Q4 2022.